NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CGON

Cg Oncology Inc

Jul 11 • 04:00PM ET

26.72

Dollar change -0.39
Percentage change -1.44	%

Healthcare • Biotechnology • USA • NASD

Peers: ONC BPMC EXEL PTCT PBYI FATE KURA MGNX GERN IMMP

| Held by: VTI VB IWM XBI VBR VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.39	Insider Own	41.12%	Shs Outstand	76.22M	Perf Week	-0.67%
Market Cap	2.04B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.02%	Shs Float	44.88M	Perf Month	-2.77%
Enterprise Value	1.35B	PEG	-	EPS next Q	-0.45	Inst Own	67.92%	Short Float	25.17%	Perf Quarter	50.28%
Income	-105.56M	P/S	3085.97	EPS this Y	-29.42%	Inst Trans	8.01%	Short Ratio	8.90	Perf Half Y	-13.83%
Sales	0.66M	P/B	2.89	EPS next Y	0.77%	ROA	-16.15%	Short Interest	11.29M	Perf YTD	-6.83%
Book/sh	9.25	P/C	2.96	EPS next 5Y	31.03%	ROE	-16.57%	52W High	40.47 -33.98%	Perf Year	-16.79%
Cash/sh	9.03	P/FCF	-	EPS past 3/5Y	-61.21% -	ROIC	-14.96%	52W Low	14.80 80.54%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-52.09% -	Gross Margin	97.89%	Volatility	4.37% 4.30%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2044.47	EPS Y/Y TTM	-	Oper. Margin	-20302.27%	ATR (14)	1.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.97	Sales Y/Y TTM	-	Profit Margin	-15945.17%	RSI (14)	54.53	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	30.97	EPS Q/Q	-103.42%	SMA20	1.90%	Beta	0.86	Target Price	55.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-90.17%	SMA50	2.91%	Rel Volume	0.38	Prev Close	27.11
Employees	113	LT Debt/Eq	0.00	Earnings	May 13 BMO	SMA200	-7.99%	Avg Volume	1.27M	Price	26.72
IPO	Jan 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.50% -72.38%	Trades		Volume	482,114	Change	-1.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$40
May-02-25	Initiated	JP Morgan	Overweight	$41
Apr-16-25	Initiated	Scotiabank	Sector Perform	$23
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Show Previous Ratings

Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
08:46AM	Loading…
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Loading…
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
08:00AM	Loading…
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POST LEONARD E	Director	May 21 '25	Option Exercise	0.60	1,000	600	1,000	May 22 04:15 PM
POST LEONARD E	Director	May 21 '25	Sale	28.00	1,000	28,000	0	May 22 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Option Exercise	0.60	1,000	600	1,000	Apr 29 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Sale	30.76	1,000	30,760	0	Apr 29 04:15 PM
POST LEONARD E	Director	Mar 17 '25	Option Exercise	0.60	1,000	600	1,000	Mar 18 04:30 PM
POST LEONARD E	Director	Mar 17 '25	Sale	28.00	1,000	28,000	0	Mar 18 04:30 PM
LEONARD E POST	Director	Mar 17 '25	Proposed Sale	27.80	4,000	111,200		Mar 17 04:38 PM
POST LEONARD E	Director	Feb 18 '25	Option Exercise	0.60	1,000	600	1,000	Feb 19 04:15 PM
POST LEONARD E	Director	Feb 18 '25	Sale	28.61	1,000	28,610	0	Feb 19 04:15 PM
POST LEONARD E	Director	Jan 13 '25	Option Exercise	0.60	1,000	600	1,000	Jan 14 04:16 PM
POST LEONARD E	Director	Jan 13 '25	Sale	29.66	1,000	29,660	0	Jan 14 04:16 PM
Song Hong Fang	Director	Dec 16 '24	Sale	28.00	700,000	19,600,000	3,003,931	Dec 17 06:03 PM
POST LEONARD E	Director	Dec 16 '24	Option Exercise	0.60	1,000	600	1,000	Dec 17 05:00 PM
POST LEONARD E	Director	Dec 16 '24	Sale	28.84	1,000	28,840	0	Dec 17 05:00 PM
POST LEONARD E	Director	Dec 06 '24	Option Exercise	0.60	1,000	600	1,000	Dec 06 06:51 PM
POST LEONARD E	Director	Dec 06 '24	Sale	34.54	1,000	34,542	0	Dec 06 06:51 PM
LEONARD E POST	Director	Dec 06 '24	Proposed Sale	33.56	4,000	134,240		Dec 06 04:32 PM
Song Hong Fang	Director	Aug 29 '24	Sale	35.36	650,455	23,000,089	586,982	Aug 30 07:18 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 08:27 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 08:26 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 06:44 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc

Upgrade your FINVIZ experience